contact us

PLEASE DO NOT LEAVE ANY CONFIDENTIAL TREATMENT DATA, PRIVATE PATIENT DETAILS OR ANY OTHER PROTECTED HEALTH INFORMATION (PHI) ON THIS SITE. THIS IS IN ORDER TO ENSURE PRIVACY AND REGULATORY COMPLIANCE WITH APPLICABLE PRIVACY RULES AND LAWS (INCLUDING BUT NOT LIMITED TO HIPAA).

Schizophrenia Negative Symptoms – Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod Hasharon, Israel

9 March, 2009

A double-blind placebo-controlled clinical trial utilizing the Brainsway®’s Deep TMS device for the treatment of negative symptoms in 45 patients with schizophrenia has begun at the Shalvata Mental Health Center.

The trial began on March 2009, and is expected to be carried out over the course of 7 weeks in respect of each subject.

This trial is expected to serve as the basis for a broad multi-center trial.